References
Racz JM, Carter JM, Degnim AC. Lobular neoplasia and atypical ductal hyperplasia on core biopsy: current surgical management recommendations. Ann Surg Oncol. 2017;24(10):2848–54. https://doi.org/10.1245/s10434-017-5978-0.
Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K. Atypical hyperplasia of the breast—risk assessment and management options. N Engl J Med. 2015;372(1):78–89. https://doi.org/10.1056/nejmsr1407164.
Amin AL, Fan F, Winblad OD, Larson KE, Wagner JL. Ipsilateral and concurrent breast cancer and atypical ductal hyperplasia: does atypia also need surgical excision? Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08896-7.
Hwang ES, Hyslop T, Lynch T, et al. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open. 2019;9(3):e026797. https://doi.org/10.1136/bmjopen-2018-026797.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
All authors have no commercial interest to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Amin, A.L., Wagner, J.L. ASO Author Reflections: ADH Upgrade Rate is Not Elevated by Presence of Ipsilateral Concurrent Breast Cancer. Ann Surg Oncol 27 (Suppl 3), 705–706 (2020). https://doi.org/10.1245/s10434-020-08947-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-08947-z